Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
The data is delayed by 15 minutes.
Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
|Shares Outstanding||EPS||-2.28||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||18630%||Sales Growth - Q/Q||283.03%||P/E||-0.22|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-112.88%||ROE||-151.51%||ROI|
|Current Ratio||3.26||Quick Ratio||3.23||Long Term Debt/Equity||Debt Ratio||0.34|
|Gross Margin||Operating Margin||-653.31%||Net Profit Margin||-656.04%||Dividend Payout Ratio|
|Cash From Financing Activities||4.29 M||Cash From Investing Activities||-70 K||Cash From Operating Activities||-3 M||Gross Profit||670 K|
|Net Profit||-3.34 M||Operating Profit||-3.28 M||Total Assets||13.8 M||Total Current Assets||11.37 M|
|Total Current Liabilities||3.49 M||Total Debt||110 K||Total Liabilities||3.52 M||Total Revenue||1.87 M|
|High 52 week||9.99||Low 52 week||0.92||Last close||1.51||Last change||-0.36%|
|RSI||54.72||Average true range||0.15||Beta||0.91||Volume||177.7 K|
|Simple moving average 20 days||3.27%||Simple moving average 50 days||15.81%||Simple moving average 200 days||-23.94%|
|Performance Week||0.3%||Performance Month||12.8%||Performance Quart||19.26%||Performance Half||-30.84%|
|Performance Year||-62.96%||Performance Year-to-date||48.49%||Volatility daily||5.3%||Volatility weekly||11.84%|
|Volatility monthly||24.27%||Volatility yearly||84.09%||Relative Volume||171.06%||Average Volume||926.47 K|
|New High||New Low|
2019-03-28 16:30:00 | Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
2019-03-27 10:15:00 | _Bull Market Hopping?_
2019-03-18 08:30:00 | Atossa Genetics Announces Receipt of $10 Million
2019-03-14 13:01:36 | What Type Of Shareholder Owns Atossa Genetics Inc.’s NASDAQ:ATOS?
2019-03-14 12:53:31 | Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing
2019-02-07 08:30:00 | Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
2019-01-30 09:15:00 | Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter
2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs
2018-12-28 07:20:00 | Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape
2018-12-19 08:05:00 | _The Roller Coaster Ride Continues_
2018-12-07 12:07:13 | Edison issues outlook on Atossa Genetics ATOS
2018-10-25 09:10:00 | Report: Exploring Fundamental Drivers Behind Atossa Genetics, Titan International, Olympic Steel, L Brands, Sysco, and TiVo — New Horizons, Emerging Trends, and Upcoming Developments
2018-09-26 09:05:00 | ''Superfirms' Domination Influences Economic Factors''
2018-09-14 09:10:00 | An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, _What Is Gynecomastia?_
2018-08-23 09:02:00 | ''Robust Economy, Resilient Market''
2018-08-21 09:05:00 | _What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?_
2018-08-01 08:00:00 | Atossa Genetics Contracts with Additional Manufacturer of Endoxifen
2018-07-31 08:15:00 | Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's — Research Highlights Growth, Revenue, and Consolidated Results
2018-07-25 09:05:00 | Vista Partners Publishes July's Macroeconomic & Investment Newsletter
2018-07-18 08:00:00 | Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program
2018-06-27 12:55:00 | ''Strong Economy, Trade Wars & Market Volatility''
2018-05-31 09:05:00 | _The Balancing Act_
2018-05-24 13:32:20 | When Should You Buy Atossa Genetics Inc NASDAQ:ATOS?
2018-05-14 16:24:51 | Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT